ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

Sino Biopharmaceutical is acquiring the remaining stake in LaNova Medicines for US $950.9 million to bolster its cancer drug ...

Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Jon Smith disagrees with the pick from ChatGPT when it comes to bargain FTSE 100 shares and counters the points made by the ...

Brigade Enterprises Ltd., Deepak Fertilizers and Petrochemicals Corp., Sun Pharmaceutical Industries Ltd. and AstraZeneca ...